Publications by authors named "D Manaka"
The clinical significance of FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan) plus anti-EGFR monoclonal antibody using cetuximab for metastatic colorectal cancer (mCRC) remains controversial. We report results from a randomized phase 2 DEEPER trial (UMIN000018217, jRCTs061180022) to test the superiority of modified (m)-FOLFOXIRI plus weekly cetuximab over bevacizumab in patients with RAS wild-type (wt) mCRC. Primary endpoint was depth of response (DpR).
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on remnant gastric cancer (RGC) which is rare, examining clinical findings, postoperative data, and challenges in its management among 313 patients from 17 Japanese institutions.
- Results show that a significant portion of patients had early-stage RGC, but disease recurrence rates were notable, especially within the first few years post-surgery, with peritoneal recurrence being the most common.
- Adjuvant chemotherapy (AC) appeared to improve recurrence-free survival significantly, suggesting that AC might offer similar benefits as in primary gastric cancer despite some limitations in the study design.
Background: Body weight loss (BWL) after gastrectomy impact on the short- and long-term outcomes. Oral nutritional supplement (ONS) has potential to prevent BWL in patients after gastrectomy. However, there is no consistent evidence supporting the beneficial effects of ONS on BWL, muscle strength and health-related quality of life (HRQoL).
View Article and Find Full Text PDFThis is a case of a 67-year-old woman diagnosed with a 35-mm pancreatic body cancer with a chief complaint of epigastric discomfort. Computed tomography demonstrated invasion of the common hepatic artery, portal vein, and stomach, and chemotherapy was initiated for locally advanced pancreatic cancer. After 9 months of chemotherapy, the tumor remained stable on imaging, and the tumor markers were within the normal range.
View Article and Find Full Text PDFAim: We evaluated the efficacy of neoadjuvant chemotherapy with intensity-modulated radiotherapy (NAC-IMRT) in patients with borderline-resectable pancreatic cancer (BRPC).
Methods: BRPC patients were treated with IMRT (45 Gy/15fr) combined with two courses of S-1 (40 mg/m bid) before surgery. Outcomes after NAC-IMRT, surgery, and survival were then evaluated.